8 completed, 4 unknown, 1 suspended. 13 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 8, Unknown 4, Suspended 1 |
| Phase 2 | 5 | Completed 3, Unknown 2 |
Follow LY6K protein, human: new trials by email Literature Review of LY6K protein, human trials Research Report on LY6K protein, human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides - Non-small Cell Lung Cancer | Phase 1 | Completed | Shiga University | 9 | 2010-02-01 | 2019-03-19 |
| Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides - Non-Small Cell Lung Cancer | Phase 1 | Completed | Shiga University | 18 | 2010-02-01 | 2019-03-19 |
| Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer URLC10, KOC1, VEGFR1 and VEGFR2 - Gastric Cancer | Phase 1 / Phase 2 | Completed | Tokyo University | 14 | 2008-05-01 | 2009-11-19 |
| Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer URLC10, VEGFR1 and VEGFR2 - Gastric Cancer | Phase 1 / Phase 2 | Completed | Tokyo University | 14 | 2008-05-01 | 2009-11-19 |
| Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer URLC10, VEGFR1 and VEGFR2 - Esophageal Cancer | Phase 1 / Phase 2 | Completed | Tokyo University | 14 | 2008-05-01 | 2009-11-19 |
| Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer URLC10, TTK and KOC1 - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Tokyo University | 14 | 2008-05-01 | 2008-05-14 |
| Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer URLC10, VEGFR1 and VEGFR2 - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Tokyo University | 14 | 2008-05-01 | 2008-05-14 |
| Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer Peptide vaccine for URLC10, Gemcitabine - Bile Duct Cancer | Phase 1 | Suspended | Akita University Hospital | 9 | 2008-02-01 | 2015-06-23 |
| Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil - Esophageal Cancer | Phase 1 | Unknown | Teikyo University | 9 | 2008-02-01 | 2011-07-21 |
| Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors 5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1 - Metastatic Tumors | Phase 1 | Completed | Kyushu University | 18 | 2007-11-01 | 2011-06-23 |
| Safety Study of Multiple Peptide Vaccine to Esophageal Cancer LY6K, VEGFR1, VEGFR2 - Esophageal Cancer | Phase 1 | Completed | Japanese Foundation for Cancer Research | 6 | 2007-10-01 | 2008-07-15 |
| Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer URLC10 - Esophageal Cancer | Phase 1 | Completed | Kinki University | 7 | 2006-11-01 | 2012-04-06 |
| Peptide Vaccination in Treating Patients With Esophageal Cancer TTK, LY6K, and IMP-3 peptides - Esophageal Cancer | Phase 1 | Unknown | University of Yamanashi | 10 | 2006-08-01 | 2008-05-29 |
Esophageal Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Lung Neoplasms (2) · Stomach Neoplasms (2) · Bile Duct Neoplasms (1) · Neoplasm Metastasis (1)
Tokyo University (5) · Shiga University (2) · Akita University Hospital (1) · Japanese Foundation for Cancer Research (1) · Kinki University (1) · Kyushu University (1) · Teikyo University (1) · University of Yamanashi (1)
Japan (13)
Naohide Yamashita, MD/PhD (4) · Yataro Daigo, MD, PhD (2) · Kenzaburo Tani, MD,phD (1) · Koji Kono, MD.PhD (1) · Kota Okinaga, MD, PhD (1) · Naohida Yamashita, MD/PhD (1) · Takuya Takayama, M.D.Ph.D (1) · Yuzo Yamamoto, MD (1)